Premium
Nilotinib treatment‐associated peripheral artery disease and sudden death: Yet another reason to stick to imatinib as front‐line therapy for chronic myelogenous leukemia
Author(s) -
Tefferi Ayalew,
Letendre Louis
Publication year - 2011
Publication title -
american journal of hematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.456
H-Index - 105
eISSN - 1096-8652
pISSN - 0361-8609
DOI - 10.1002/ajh.22051
Subject(s) - nilotinib , medicine , front line , imatinib , chronic myelogenous leukemia , dasatinib , leukemia , peripheral , first line therapy , disease , imatinib mesylate , oncology , myeloid leukemia , political science , law
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom